An observational study in Acute Hypoxemic Respiratory Failure, Non Invasive Ventilation (NIV) and Bioimpedance Measurement Capacity, sponsored by Hospital Universitari de Bellvitge. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Hospital Universitari de Bellvitge · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Respiratory Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Respiratory Insufficiency · Spain.
Among the 69 studies in Respiratory Insufficiency with a site in Spain, this one is the 10th largest by planned enrollment of the 31 observational ones that give a count, is one of 5 that started in 2025, is one of 31 observational ones, reaches primary completion later than 7 of the 14 other live ones, and was the 62nd registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →11 of the 69 studies in Respiratory Insufficiency with a site in Spain are open now. Recruiting first, the newest first:
Hospital del Mar Research Institute (IMIM) · Sites in Spain
Ages 18+
Medipol University · Sites in Spain, Chile, Egypt and 3 more countries
Ages 18–89
Centro de Emergencias Sanitarias 061 Andalucía · Sites in Spain
BioAegis Therapeutics Inc. · Sites in Spain, United States, Belgium and 10 more countries
Ages 18+
University Health Network, Toronto · Sites in Spain, United States, Australia and 7 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 100 across 456 observational studies indexed under Respiratory Insufficiency.
Median enrollment 116 across the 38 interventional studies, 298 across the 31 observational. Of the 42 that completed or were terminated, 6 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 69 have an industry lead sponsor. The 10 most frequent:
Hospital Universitari de Bellvitge is the lead sponsor of 120 studies on the registry; 29 are open to participants now.
Hospital Universitari de Bellvitge has 2 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Insufficiency with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07679646Air Liquide Healthcare SpainEffectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO) | 2026-12 |
| NCT07098611Medipol UniversityA New Tool for Extubation Readiness in Mechanically Ventilated Patients: Readiness for EXtubation Score | 2026-12-30 |
| NCT07178483Hospital Universitari de BellvitgeEvaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure | 2027-03-01 |
| NCT05440851University Health Network, TorontoPlatform of Randomized Adaptive Clinical Trials in Critical Illness | 2027-03-31 |
| NCT07708506Jesus VillarIs Hypoxemia Driving Outcome in Acute Hypoxemic Respiratory Failure? (HOMELAND Study) | 2027-07-29 |
Add all 7 to your calendar (.ics) → With an account.
Among the 69 studies in Respiratory Insufficiency with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
NIVAR01 (Multimodal evaluation of physical capacity and energy requirements in patients with hypoxemic acute respiratory failure and community acquired pneumonia under non invasive ventilation support) aims to comprehensively assess energy requirements and physical capacity in patients with acute hypoxemic respiratory failure (AHRF) due to community-acquired pneumonia (CAP) undergoing non-invasive ventilation (NIV).
Through a stepwise, multimodal approach integrating physiological measurements, imaging, and molecular biomarkers, the project seeks to identify patient subphenotypes that can guide targeted interventions, improve outcomes, and reduce the need for invasive mechanical ventilation. The project is structured in five progressive phases, each building on the findings of the previous one to refine and personalize care strategies.
The first phase of the project aims to assess the correlation between BIA (bioelectrical impedance analysis) and IC (indirect calorimetry) in sedated patients, in oder to extrapolate this correlation in patients under NIV in the next phase.
The second phase uses this correlation to validate the use of indirect calorimetry (IC) in patients under non-invasive ventilation (NIV) by comparing it with data obtained from patients under invasive mechanical ventilation, where IC is better established and technically more accurate. This comparative approach will serve to assess the reliability and feasibility of IC in NIV settings, incorporating correction factors for air leaks and comparing with BIA data, laying the groundwork for its integration with other physiological and biochemical measurements in subsequent phases.
The third phase expands to a multimodal prospective observational cohort study integrating IC, BIA, ultrasound, biomarkers of mitochondrial and endothelial dysfunction, and innate immune system paralysis. These data will be used for patient phenotyping through advanced machine learning. The fourth and fifth phases will develop and test personalized nutritional and motor interventions (e.g., phrenic nerve stimulation, tailored physiotherapy) in clinical trials based on identified patient subtypes.
Previous studies (Georges et al., Siirala et al., Singer 2024) have demonstrated the feasibility of using IC in NIV patients, although limited by methodological constraints. This project brings novelty by incorporating BIA-derived metabolic rate estimates and segmental analysis, offering new insights into body composition, fluid balance, and muscle integrity, including diaphragm function.
Additionally, biomarkers such as cf-mtDNA, FGF-21, GDF-15, HSP60/10, and cytokine profiles (TNFα, IL-6, IL-10, CRP), as well as endothelial markers (e-Selectin, sICAM-1, vCAM-1, Syndecan-1), will be analyzed. Immune paralysis will be studied via monocyte HLA-DR expression and LPS-stimulated cytokine release.
By leveraging multimodal data integration and gender-specific analysis, NIVAR 01 aims to optimize prediction of NIV failure beyond current tools such as the HACOR index and enable individualized patient management.
Non-invasive ventilation (NIV) is widely used in patients with acute hypoxemic respiratory failure (AHRF), particularly those with community-acquired pneumonia (CAP), as a strategy to avoid intubation and invasive mechanical ventilation. However, predicting NIV failure remains a significant clinical challenge, and the existing tools, such as the HACOR index, are limited in accuracy and do not take into account crucial aspects like energy expenditure, muscle integrity, or other patient's physiological parameters.
NIVAR01 addresses this gap through a comprehensive, stepwise research plan aimed at understanding and anticipating NIV failure by integrating metabolic, physiological, imaging, and biomolecular data. The ultimate goal is to define patient subphenotypes that enable the personalization of therapy and improve clinical outcomes.
Objectives
The main objective of NIVAR 01 is to develop and validate a multimodal strategy to predict NIV failure in patients with AHRF and CAP, enabling the design of personalized therapeutic interventions. Specifically, the project aims to:
Planning
The project is structured in five sequential phases, each building upon the results of the previous one. The approach moves from methodological validation to biological characterization and finally to clinical intervention. It will integrate sex-specific analysis into predictive models and intervention strategies.
- Phase 1: Correlation between BIA and IC in sedated patients
The project begins by evaluating the correlation between metabolic rate data obtained from BIA and from indirect calorimetry in sedated, invasively ventilated ICU patients. Since IC is a robust validated method in this setting, it will serve as the reference method. The correlation obtained will validate the accuracy of BIA and support its use in future phases.
- Phase 2: Validation of IC in patients under NIV
Using the reference from Phase 1, IC will be adapted for use in patients under NIV. This includes addressing the challenges posed by air leaks through integration of correction factors provided by ventilator device and its monitoring software, and potentially the development of specific circuit adaptors if required. The metabolic data collected via IC will be compared with BIA estimates to confirm feasibility and reliability in the NIV setting.
- Phase 3: Multimodal cohort study and patient phenotyping
In a prospective observational study, a cohort of patients with AHRF and CAP under NIV will undergo multimodal evaluation. This includes IC, BIA (with segmental analysis of the different body compartments both at the anatomic and physiological level), muscle and diaphragm ultrasound, and blood sampling for biomarkers of mitochondrial dysfunction (cf-mtDNA, FGF-21, GDF-15, HSP60/10), endothelial injury (e-Selectin, sICAM-1, vCAM-1, Syndecan-1), oxidative stress, and immune paralysis (HLA-DR expression, TNFα response to LPS). Data will be analyzed using machine learning to identify patient subphenotypes.
- Phase 4: Design of personalized interventions
Based on the phenotypes identified, targeted interventions will be developed. These include nutritional strategies informed by metabolic requirements and muscle function assessments, as well as physiotherapy protocols that may involve early mobilization and respiratory muscle stimulation (e.g., phrenic nerve). Strategies will be adapted to sex-specific physiological patterns and the patient's compartmental body composition.
- Phase 5: Randomized controlled trials
In the final phase, the proposed interventions will be tested in randomized clinical trials (RCTs). Patients will be stratified by phenotype and randomized to receive standard care or personalized therapy. Primary outcomes will include NIV failure (need for intubation), ICU/hospital length of stay, mortality, and functional recovery.
Expected Outcomes
NIVAR 01 is expected to generate:
This integrated model will help clinicians anticipate NIV failure earlier, adapt treatment proactively, and improve patient outcomes through individualized care strategies.
Conclusion
NIVAR01 aims to develop a new standard in the management of patients with acute respiratory failure under non-invasive ventilation. By combining validated physiological measurements, molecular biomarkers, and clinical decision tools, the project introduces a precision medicine approach to intensive care. Through systematic validation, rigorous phenotyping, and targeted interventions, NIVAR 01 aims to reduce NIV failure, shorten ICU stays, and improve survival and recovery in this patient population.
Patients admitted to critical care units requiring NIV support due to CAP and hypoxemic acute respiratory failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NIV FAILURE
ENDOTRACHEAL INTUBATION OR DEATH WHILE RECEIVING NIV
Time frame: 1 MONTH
ICU LENGHT OF STAY
DAYS IN ICU WILL BE REGISTERED.
Time frame: Through study completion, an average of 1 year
HOSPITAL LENGTH OF STAY
DAYS ADMITTED IN HOSPITAL
Time frame: Through study completion, an average of 1 year.
Plan to share: Undecided
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.
Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 24 months is close to that.
Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitari de Bellvitge →